Literature DB >> 20032317

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.

Aditya H Gaur, Bindiya Bagga, Subrata Barman, Randall Hayden, Aubrey Lamptey, James M Hoffman, Deepa Bhojwani, Patricia M Flynn, Elaine Tuomanen, Richard Webby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20032317     DOI： 10.1056/NEJMc0910893

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  45 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Authors:  Elena A Govorkova; Bindumadhav M Marathe; Ashley Prevost; Jerold E Rehg; Robert G Webster
Journal:  Antiviral Res       Date:  2011-05-27       Impact factor: 5.970

3.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

4.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

Review 5.  Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors:  Roy F Chemaly; Dimpy P Shah; Michael J Boeckh
Journal:  Clin Infect Dis       Date:  2014-11-15       Impact factor: 9.079

Review 6.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

7.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

8.  A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Authors:  E Bart Tarbet; Stephanie Hamilton; Almut H Vollmer; Angela Luttick; Wy Ching Ng; Melinda Pryor; Brett L Hurst; Simon Crawford; Donald F Smee; Simon P Tucker
Journal:  J Antimicrob Chemother       Date:  2014-04-28       Impact factor: 5.790

9.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

10.  The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Authors:  Fred Y Aoki; Upton D Allen; H Grant Stiver; Gerald A Evans
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.